CODA Biotherapeutics’ Chemogenetic Gene Therapy Platform Can Control Focal Seizures in vivo

SOUTH SAN FRANCISCO, Calif.: SOUTH SAN FRANCISCO, Calif., Dec. 7, 2021 /PRNewswire/ -- CODA Biotherapeutics, Inc. ("CODA"), today announced the presentation of preclinical data suggesting that the Company's chemogenetic gene therapy platform can control focal seizures in vivo. Collectively, the results showed efficacy of the CODA chemogenetic approach in controlling...

Click to view original post